BRPI0919268A8 - Aptâmero que se liga ao ngf e medicamento - Google Patents

Aptâmero que se liga ao ngf e medicamento

Info

Publication number
BRPI0919268A8
BRPI0919268A8 BRPI0919268A BRPI0919268A BRPI0919268A8 BR PI0919268 A8 BRPI0919268 A8 BR PI0919268A8 BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A8 BRPI0919268 A8 BR PI0919268A8
Authority
BR
Brazil
Prior art keywords
aptamer
ngf
drug
inhibitory activity
activity against
Prior art date
Application number
BRPI0919268A
Other languages
English (en)
Inventor
Jin Ling
Miyakawa Shin
Fujiwara Masatoshi
Nakamura Yoshikazu
Hiramatsu Hisanao
Original Assignee
Fujimoto Seiyaku Kk
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujimoto Seiyaku Kk, Ribomic Inc filed Critical Fujimoto Seiyaku Kk
Publication of BRPI0919268A2 publication Critical patent/BRPI0919268A2/pt
Publication of BRPI0919268A8 publication Critical patent/BRPI0919268A8/pt
Publication of BRPI0919268B1 publication Critical patent/BRPI0919268B1/pt
Publication of BRPI0919268B8 publication Critical patent/BRPI0919268B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

APTÂMERO PARA NGF E USO DESTE. A presente invenção refere-se a um aptâmero tendo uma atividade inibitória contra NGF; um complexo contendo um aptâmero tendo uma atividade de ligação ou atividade inibitória contra NGF e uma substância funcional (por exemplo, substâncias de afinidade, substâncias de etiquetação, enzimas, veículos de distribuição de fármaco, fármacos e similares); um medicamento, um agente diagnóstico, um agente de etiquetação e similares contendo um aptâmero tendo uma atividade de ligação ou atividade inibitória contra NGF, ou um complexo contendo o aptâmero e a substância funcional; e similares.
BRPI0919268A 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento BRPI0919268B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008244982 2008-09-24
JP2008-244982 2008-09-24
PCT/JP2009/066457 WO2010035725A1 (ja) 2008-09-24 2009-09-18 Ｎｇｆに対するアプタマー及びその使用

Publications (4)

Publication Number Publication Date
BRPI0919268A2 BRPI0919268A2 (pt) 2017-11-07
BRPI0919268A8 true BRPI0919268A8 (pt) 2018-02-06
BRPI0919268B1 BRPI0919268B1 (pt) 2021-01-12
BRPI0919268B8 BRPI0919268B8 (pt) 2021-05-25

Family

ID=42059724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919268A BRPI0919268B8 (pt) 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento

Country Status (16)

Country Link
US (1) US10260070B2 (pt)
EP (1) EP2354225B1 (pt)
JP (1) JP5602020B2 (pt)
KR (1) KR101694559B1 (pt)
CN (1) CN102171339B (pt)
AU (1) AU2009297626B2 (pt)
BR (1) BRPI0919268B8 (pt)
CA (1) CA2738129C (pt)
DK (1) DK2354225T3 (pt)
ES (1) ES2543222T3 (pt)
HU (1) HUE026595T2 (pt)
IL (1) IL211929A0 (pt)
MX (1) MX2011003144A (pt)
RU (1) RU2011116175A (pt)
WO (1) WO2010035725A1 (pt)
ZA (1) ZA201102682B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
AU2011230388B2 (en) * 2010-03-24 2016-09-08 Fujimoto Pharmaceutical Corporation Aptamer for NGF and use thereof
NZ602618A (en) * 2010-04-12 2013-12-20 Somalogic Inc Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
JP5696830B2 (ja) * 2010-04-27 2015-04-08 株式会社アップウェル Ｐａｒ−２活性化阻害物質
JP2012024026A (ja) * 2010-07-23 2012-02-09 Tdk Corp Ｓｍ菌特異的アプタマー、Ｓｍ菌増殖抑制剤及びＳｍ菌の検出方法
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
EP2762569B1 (en) 2011-09-28 2018-06-13 RIBOMIC Inc. Ngf aptamer and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE315101T1 (de) 1992-09-29 2006-02-15 Gilead Sciences Inc Nukleinsäureliganden und ihre herstellungsmethoden
EP0724647A4 (en) 1993-09-08 2003-09-17 Gilead Sciences Inc NUCLEIC ACIDS AS LIGANDS AND IMPROVED PRODUCTION METHODS
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US7638464B2 (en) * 1999-04-26 2009-12-29 Biocept, Inc. Three dimensional format biochips
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050215506A1 (en) * 2001-12-20 2005-09-29 Bennett C F Modulation of tyrosinase expression
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US7592441B2 (en) * 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
ES2397715T3 (es) 2006-11-14 2013-03-08 Ribomic Inc Aptámero contra midkina y uso del mismo
JP5012135B2 (ja) 2007-03-28 2012-08-29 コニカミノルタアドバンストレイヤー株式会社 超深度画像生成装置
WO2010008001A1 (ja) 2008-07-14 2010-01-21 国立大学法人 東京大学 Ｉｌ－１７に対するアプタマー及びその使用

Also Published As

Publication number Publication date
US20110251266A1 (en) 2011-10-13
HUE026595T2 (hu) 2016-06-28
RU2011116175A (ru) 2012-10-27
BRPI0919268B1 (pt) 2021-01-12
WO2010035725A1 (ja) 2010-04-01
EP2354225A4 (en) 2012-03-21
JP5602020B2 (ja) 2014-10-08
CN102171339A (zh) 2011-08-31
DK2354225T3 (en) 2015-06-29
EP2354225A9 (en) 2012-06-27
AU2009297626B2 (en) 2016-01-14
BRPI0919268B8 (pt) 2021-05-25
AU2009297626A2 (en) 2011-05-19
EP2354225B1 (en) 2015-04-22
ES2543222T3 (es) 2015-08-17
KR101694559B1 (ko) 2017-01-09
CN102171339B (zh) 2017-06-09
JPWO2010035725A1 (ja) 2012-02-23
ZA201102682B (en) 2012-06-27
CA2738129C (en) 2017-11-14
IL211929A0 (en) 2011-06-30
US10260070B2 (en) 2019-04-16
MX2011003144A (es) 2011-05-19
AU2009297626A1 (en) 2010-04-01
BRPI0919268A2 (pt) 2017-11-07
EP2354225A1 (en) 2011-08-10
KR20110059888A (ko) 2011-06-07
CA2738129A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0919268B8 (pt) aptâmero que se liga ao ngf e medicamento
MY147374A (en) Aptamer against midkine and use thereof
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
MX2009002937A (es) Metodo y sistema para infusion controlada de substancias terapeuticas.
BR112012010534A2 (pt) "dispositivo de fornecimento de fármaco e método de montagem"
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
BRPI0517569A (pt) uso de um ligando, ligando, composição farmacêutica, e, dispositivo de distribuição de drogas
BR112012027651A2 (pt) método, e, sistema
WO2008112164A3 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CL2008000377A1 (es) Compuestos derivados de ciclos fusionados sustituidos; agente farmaceutico que comprende a dichos compuestos; y uso para la prevencion o tratamiento de la diabetes.
BR112012013975A2 (pt) anticorpos monoclonais que se ligam b7h6 e usos dos mesmo
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CR10032A (es) Preparación sólida
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
AR077049A1 (es) Aptamero contra quimasa y su uso
BR112012026724A2 (pt) combinação de fármcos com pró-fármacos ligados à proteína
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BRPI0819235A2 (pt) Sistema de distribuição transdérmica para hormônios e esteróides
BRPI0719972B8 (pt) dispositivo de acesso vascular para deslocamento de fluído estagnado
BRPI1100012A2 (pt) agente para realçar a expressão de fatores associados com redox
BR112014014973A8 (pt) preparações contendo emodepside amorfo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP)

B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP) , FUJIMOTO PHARMACEUTICAL CORPOR

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.